Last edition
News about "Amlitelimab"
Sanofi to not Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews
Sanofi will not seek global regulatory approval for amlitelimab in Atopic Dermatitis (AD) after efficacy and safety data did not support further development.
Amlitelimab | 27/07/2026 | By News Bureau | 108
Sanofi's Amlitelimab Achieves Key Milestone in Phase-III Trial for Atopic Dermatitis
Sanofi’s amlitelimab demonstrates sustained efficacy and improved disease outcomes, highlighting the potential to reshape the treatment for atopic dermatitis.
Amlitelimab | 04/09/2025 | By Dineshwori | 409
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy